BS
BSPM.US Biostar Pharmaceuticals Inc
- Market cap
- USD 263.00
- P/E
- -
- P/B
- 0.01x
- ROE
- -9.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2017.
Is BSPM.US undervalued?
Graham numberThe Graham number of Biostar Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Biostar Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Biostar Pharmaceuticals Inc yet.
Biostar Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Biostar Pharmaceuticals Inc
Biostar Pharmaceuticals, Inc. develops, manufactures, and markets pharmaceutical products for various diseases and conditions in the People's Republic of China. The company principally offers Xin Ao Xing Oleanolic Acid capsule, an OTC medicine for chronic hepatitis B. It also provides OTC products, such as Ganwang compound paracetamol and amantadine hydrochloride capsule for the relief of common cold, runny nose, sore throat, headache, and fever; Tianqi Dysmenorrhea capsule,…
Full company profileBiostar Pharmaceuticals Inc financial statements
2017 annualized: Fiscal year 2017 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2017, the balance sheet is the latest quarter. Figures change when the annual report is published.
Biostar Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 15.9M | 33.9M | 53.3M | 80.2M | 92.0M | 49.3M | 52.7M | 61.4M | 27.1M | 2.38M | 424K |
| Gross Profit | 10.7M | 19.9M | 39.0M | 60.1M | 64.4M | 29.9M | 25.7M | 30.3M | 11.1M | 915K | -49.0K |
| Operating Income | 4.85M | 7.76M | 15.1M | 23.6M | 18.2M | -20.2M | 508K | -1.31M | -23.8M | -3.56M | -4.19M |
| EBITDA | 5.44M | 8.41M | 15.7M | 24.1M | 19.0M | -19.7M | 5.81M | 4.78M | -21.2M | -1.70M | -1.91M |
| Net Income | 3.96M | 6.69M | 10.5M | 17.4M | 12.2M | -20.0M | 809K | 4.85M | -25.1M | -5.70M | -3.33M |
| EPS | 3.99 | 6.04 | 9.06 | 13 | 9.17 | -15 | 0.49 | 2.34 | -11 | -2.48 | -1.26 |
| Balance Sheet | |||||||||||
| Total Assets | 20.2M | 29.0M | 47.0M | 68.1M | 83.1M | 70.5M | 67.6M | 81.2M | 51.4M | 42.5M | 41.4M |
| Total Liabilities | 3.96M | 5.72M | 6.09M | 7.59M | 6.66M | 12.7M | 4.79M | 8.91M | 7.10M | 5.62M | 5.28M |
| Shareholders' Equity | 16.3M | 23.3M | 40.9M | 60.5M | 76.4M | 57.8M | 62.8M | 72.3M | 44.3M | 36.9M | 36.1M |
| Cash & Short-term Investments | 2.29M | 758K | 8.58M | 13.2M | 17.0M | 1.76M | 80.1K | 1.69M | 38.9K | 173K | 365K |
| Total Debt | 520K | - | - | - | 787K | 6.34M | - | 3.09M | 2.77M | 2.33M | 2.43M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 1.31M | -779K | 5.67M | 12.8M | 8.77M | -3.58M | 8.91M | 3.31M | 5.88M | 4.91M | 6.11M |
| Capital Expenditure | 86.3K | 328K | 2.36M | 4.00M | 3.23M | 32.9K | 982K | 2.87M | 59.5K | 0.00 | 5.88M |
| Free Cash Flow | 1.22M | -1.11M | 3.32M | 8.84M | 5.54M | -3.62M | 7.93M | 441K | 5.82M | 4.91M | 6.11M |
| Ratios | |||||||||||
| ROE | 24.3% | 28.7% | 25.7% | 28.7% | 15.9% | -34.6% | 1.3% | 6.7% | -56.7% | -15.5% | -9.2% |
| ROA | 19.6% | 23.1% | 22.3% | 25.5% | 14.7% | -28.4% | 1.2% | 6.0% | -48.9% | -13.4% | -8.0% |
| Net Profit Margin | 25.0% | 19.7% | 19.7% | 21.7% | 13.2% | -40.5% | 1.5% | 7.9% | -92.6% | -239.0% | -786.5% |
| Debt to Equity | 0.03x | - | - | - | 0.01x | 0.11x | - | 0.04x | 0.06x | 0.06x | 0.07x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Biostar Pharmaceuticals Inc dividends
Biostar Pharmaceuticals Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:7 on Feb 5, 2016.
Who owns Biostar Pharmaceuticals Inc
Ownership data of Biostar Pharmaceuticals Inc is not available yet.
Biostar Pharmaceuticals Inc company profile
- Company name
- Biostar Pharmaceuticals Inc
- Ticker
- BSPM.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 200
- Fiscal year end
- December
- Address
- No. 588 Shiji Xi Road, Xianyang, China, 712046
- Phone
- 86 29 3368 6638
- Website
- biostarpharmaceuticals.com
About Biostar Pharmaceuticals Inc
Biostar Pharmaceuticals, Inc. develops, manufactures, and markets pharmaceutical products for various diseases and conditions in the People's Republic of China. The company principally offers Xin Ao Xing Oleanolic Acid capsule, an OTC medicine for chronic hepatitis B. It also provides OTC products, such as Ganwang compound paracetamol and amantadine hydrochloride capsule for the relief of common cold, runny nose, sore throat, headache, and fever; Tianqi Dysmenorrhea capsule, a traditional Chinese medicine used for pain and other symptoms associated with menstruation; Deafness Tongqiao pills for hepatobiliary Huosheng, head swelling, deafness and tinnitus, ear pus, dry stool, and urine-yellow; Wenweishu capsules for the treatment of chronic gastritis and pain of epigastric cold; Zhitongtougu ointment for treating joint pain, swelling, tenderness, or dysfunction; and Chuzhang Zehaifu tablets for cataract. In addition, the company provides prescription pharmaceutical products, including Danshen granules; Taohuasan pediatric medicines; Jingang tablets; Danxiang Rhinitis tablets; Yanlixiao capsules; Piracetam tablets; Huangyangning tablets; Hyperthyroidism capsules; Fosfomycin Calcium capsules; Qianlietong capsules; Yituo Erythromycin particles; Danshen tablets; Muxiang Shunqi pills; Sifangwei capsules; and Aspirin Enteric-coated tablets. It sells its products through distributors and website that serves as internet-based China Hepatitis Internet Hospital, which offers HBV patients with information on HBV and treatment options, as well as methods to purchase HBV medicines. The company was incorporated in 2007 and is headquartered in Xianyang, the People's Republic of China.
Biostar Pharmaceuticals Inc management
5- Mr. Ronghua Wang Ph.D.Chairman, CEO & President · born 1956
- Mr. Zhenghong WangChief Operating Officer · born 1980
- Ms. Xiaojuan ZhaiChief Financial Officer · born 1989
- Prof. Xiaohui ZhengChief Scientist · born 1968
- Ms. Shuang GongDirector of Administration & Secretary of Board · born 1967